Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 5/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | PRKX | P51817 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253952 | 0.81 | NUDT1 (0.49) | NUDT1JAK1PDE10ACHEK1MET | |
| SCHEMBL19761029 | 0.81 | LMNA (0.38) | PDE10AEGLN2HPGDLMNAMAPT | |
| SCHEMBL2788772 | 0.78 | NUDT1 (0.43) | NUDT1JAK1PDE10ACHEK1MET | |
| SCHEMBL16439357 | 0.75 | PIK3CG (0.33) | PIK3CG | |
| SCHEMBL16439330 | 0.75 | EGLN2 (0.40) | EGLN2PIK3CG | |
| SCHEMBL16439305 | 0.74 | NUDT1 (0.38) | NUDT1JAK1PDE10AEGLN2KDM4E | |
| SCHEMBL31489520 | 0.74 | KDM4E (0.41) | PDE10AKDM4E | |
| SCHEMBL31586392 | 0.74 | JAK1 (0.37) | NUDT1JAK1PDE10AEGLN2 | |
| SCHEMBL25646677 | 0.71 | LRRK2 (0.40) | NUDT1JAK1PDE10ALRRK2 | |
| SCHEMBL30888369 | 0.69 | F2 (0.38) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | claimed |
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | claimed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | claimed |
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12084453-B2 | Bicyclic amines as CDK12 inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2023107705-A1 | BICYCLIC AMINES AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183251-A1 | BICYCLIC AMINES AS CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-15 | — | — | US | disclosed |
| WO-2015014283-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | 南京圣和药业股份有限公司 (CN) | 2015-02-05 | — | — | WO | disclosed |
| EP-2507233-B1 | Substituted triazolopyridines | BAYER IP GMBH (DE) | 2013-11-06 | — | — | EP | disclosed |
| EP-2507233-B1 | Substituted triazolopyridines | BAYER IP GMBH (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-8551980-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8263595-B2 | Triazolopyridine compounds and their use as ask inhibitors | MERCK SERONO SA (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2343294-A1 | Substituted triazolopyridines | Bayer Schering Pharma AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011063907-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011063907-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | disclosed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183251-A1 | BICYCLIC AMINES AS CDK12 INHIBITORS | CDK12, CDK1, CDK2 | NUDT1 1270/4885JAK1 672/4885PDE10A 2698/4885 |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MAP3K5, MAPKAPK5, MAP3K9 | NUDT1 2072/4885JAK1 229/4885PDE10A 1394/4885 |
| US-12084453-B2 | Bicyclic amines as CDK12 inhibitors | CDK12, CDK1, CDK2 | NUDT1 1270/4885JAK1 672/4885PDE10A 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.